Institut für Experimentelle und Klinische Pharmakologie und Toxikologie

Gut-specific histamine 3 receptor signaling orchestrates microglia-dependent resolution of peripheral inflammation (2025) Dürholz K, Ehnes L, Linnerbauer M, Schmid E, Danzer H, Hinzpeter-Schmidt M, Lößlein L, et al. Journal article Distinct functional cerebral hypersensitivity networks during incisional and inflammatory pain in rats (2025) Kreitz S, Pradier B, Segelcke D, Amirmohseni S, Heß A, Faber C, Pogatzki-Zahn EM Journal article Pseudo-Worsening of Kidney Function (2025) Fromm M, Sponfeldner M, Dörje F, Geßner K, Dürr P, Cuba L, Schwanfelder J Journal article, Letter Clinical–pharmaceutical assessment of medication CDSS alerts: content appropriateness and patient relevance in clinical practice (2025) Bauer J, Busse M, Koch S, Schmid M, Sommer J, Fromm M, Dörje F Journal article Physicians' and pharmacists' perspective on clarity and clinical relevance of absolute contraindications in “Summaries of Product Characteristics” (2025) Andrikyan W, Sponfeldner M, Jung-Poppe L, Dürr P, Straubmeier MI, Schuster AK, Weisbach L, et al. Journal article Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data (2025) Sponfeldner M, Dürr P, Lensker P, Geßner K, Cuba L, Fietkau R, Neurath M, et al. Journal article Quality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training (2025) Wiederstein S, Grasl S, Rappold V, Stueckler J, Schneeberger R, Mueller CA, Renner B Journal article From whole-brain metrics to circuitspecific precision: advancing fMRI biomarkers for TNF inhibitor response in rheumatoid arthritis – Authors' reply (2025) Heß A, Tascilar K, Schett G, Rech J Journal article Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics (2025) Cuba L, Dörje F, Kramer R, Dürr P, Erdmann M, Fromm M, Berking C, Geßner K Journal article Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study (2025) Heß A, Tascilar K, Schenker H, Konerth L, Schönau V, Sergeeva M, Kreitz S, et al. Journal article